Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Elan, J&J alliance Has Tysabri Option

by Ann M. Thayer
July 27, 2009 | A version of this story appeared in Volume 87, Issue 30

Johnson & Johnson's $1.5 billion deal with Elan, it turns out, includes more than just Elan's Alzheimer's program (C&EN, July 13, page 8). Terms also touch on Tysabri, a multiple sclerosis drug developed by Elan and Biogen Idec that had about $500 million in first-half 2009 sales. Under a 2001 contract, Biogen and Elan have the right to buy out the other's Tysabri share if ownership changes at either firm. In last week's second-quarter earnings conference call, Elan revealed that it has given J&J the option to finance the purchase of Biogen's half, if the opportunity arises, and then own the drug equally with Elan. Before the J&J deal, debt-ridden Elan seemed unlikely to acquire Tysabri, a move that would reduce the value of Biogen to potential buyers.—AMT

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.